SignalXSignalX

SYK Stryker Corporation

FY2025 10-K
Filed: Feb 11, 2026
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR
Stryker Corporation Overview

Stryker Corporation (SYK) filed its fiscal year 2025 10-K annual report with the SEC on Feb 11, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • • Core business model focused on medical technology and device manufacturing, emphasizing innovation and compliance
  • • No new products, services, or segments explicitly introduced or emphasized in the 2026 filing
+3 more insights

Management Discussion & Analysis

  • • Revenue $18.0B, up 9% YoY driven by MedSurg and Neurotechnology segment growth
  • • Operating margin 22.5% vs 21.0% YoY due to product mix and cost management
+3 more insights

Risk Factors

  • • Regulatory risk: EU medical device regulations require costly quality system updates, labeling changes, and remanufacturing impacting R&D and compliance expenses in 2025
  • • Geopolitical/macroeconomic risk: Foreign currency fluctuations affected net sales by ±0.5%, with 10.7% growth in constant currency highlighting sensitivity to exchange rates
+3 more insights

Financial Summary
XBRL

Revenue

$25.1B

Net Income

$3.2B

Gross Margin

64.0%

Operating Margin

19.5%

Net Margin

12.9%

ROE

14.5%

Total Assets

$47.8B

EPS (Diluted)

$8.40

Operating Cash Flow

$5.0B

Source: XBRL data from Stryker Corporation FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on Stryker Corporation

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available